222 related articles for article (PubMed ID: 34830188)
1. Genetic and Enzymatic Characteristics of CYP2A13 in Relation to Lung Damage.
Vrzal R
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830188
[TBL] [Abstract][Full Text] [Related]
2. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary expression of CYP2A13 and ABCB1 is regulated by FOXA2, and their genetic interaction is associated with lung cancer.
Xiang C; Wang J; Kou X; Chen X; Qin Z; Jiang Y; Sun C; Xu J; Tan W; Jin L; Lin D; He F; Wang H
FASEB J; 2015 May; 29(5):1986-98. PubMed ID: 25667220
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 2A13 enhances the sensitivity of human bronchial epithelial cells to aflatoxin B1-induced DNA damage.
Yang X; Zhang Z; Wang X; Wang Y; Zhang X; Lu H; Wang SL
Toxicol Appl Pharmacol; 2013 Jul; 270(2):114-21. PubMed ID: 23602888
[TBL] [Abstract][Full Text] [Related]
5. CYP2A6: genetics, structure, regulation, and function.
Raunio H; Rahnasto-Rilla M
Drug Metabol Drug Interact; 2012 May; 27(2):73-88. PubMed ID: 22706231
[TBL] [Abstract][Full Text] [Related]
6. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Zhang X; D'Agostino J; Wu H; Zhang QY; von Weymarn L; Murphy SE; Ding X
J Pharmacol Exp Ther; 2007 Nov; 323(2):570-8. PubMed ID: 17671098
[TBL] [Abstract][Full Text] [Related]
7. The missense genetic polymorphisms of human CYP2A13: functional significance in carcinogen activation and identification of a null allelic variant.
Wang SL; He XY; Shen J; Wang JS; Hong JY
Toxicol Sci; 2006 Nov; 94(1):38-45. PubMed ID: 16917071
[TBL] [Abstract][Full Text] [Related]
8. Structure, function, regulation and polymorphism of human cytochrome P450 2A6.
Di YM; Chow VD; Yang LP; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):754-80. PubMed ID: 19702528
[TBL] [Abstract][Full Text] [Related]
9. Structure of the human lung cytochrome P450 2A13.
Smith BD; Sanders JL; Porubsky PR; Lushington GH; Stout CD; Scott EE
J Biol Chem; 2007 Jun; 282(23):17306-13. PubMed ID: 17428784
[TBL] [Abstract][Full Text] [Related]
10. Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model.
Megaraj V; Zhou X; Xie F; Liu Z; Yang W; Ding X
Carcinogenesis; 2014 Jan; 35(1):131-7. PubMed ID: 23917075
[TBL] [Abstract][Full Text] [Related]
11. Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers.
D'Agostino J; Zhang X; Wu H; Ling G; Wang S; Zhang QY; Liu F; Ding X
Drug Metab Dispos; 2008 Nov; 36(11):2316-23. PubMed ID: 18669584
[TBL] [Abstract][Full Text] [Related]
12. Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan.
Tamaki Y; Arai T; Sugimura H; Sasaki T; Honda M; Muroi Y; Matsubara Y; Kanno S; Ishikawa M; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2011; 26(5):516-22. PubMed ID: 21791872
[TBL] [Abstract][Full Text] [Related]
13. Benzylmorpholine analogs as selective inhibitors of lung cytochrome P450 2A13 for the chemoprevention of lung cancer in tobacco users.
Blake LC; Roy A; Neul D; Schoenen FJ; Aubé J; Scott EE
Pharm Res; 2013 Sep; 30(9):2290-302. PubMed ID: 23756756
[TBL] [Abstract][Full Text] [Related]
14. Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human peripheral lung microsomes.
Brown PJ; Bedard LL; Reid KR; Petsikas D; Massey TE
Drug Metab Dispos; 2007 Nov; 35(11):2086-94. PubMed ID: 17717079
[TBL] [Abstract][Full Text] [Related]
15. miR-138-1* regulates aflatoxin B1-induced malignant transformation of BEAS-2B cells by targeting PDK1.
Wang Y; Zhang Z; Wang H; Zhang Y; Ji M; Xu H; Wang C; Sun Z; Gao W; Wang SL
Arch Toxicol; 2016 May; 90(5):1239-49. PubMed ID: 26084420
[TBL] [Abstract][Full Text] [Related]
16. Inhibition and inactivation of cytochrome P450 2A6 and cytochrome P450 2A13 by menthofuran, β-nicotyrine and menthol.
Kramlinger VM; von Weymarn LB; Murphy SE
Chem Biol Interact; 2012 May; 197(2-3):87-92. PubMed ID: 22486895
[TBL] [Abstract][Full Text] [Related]
17. Association between CYP2A13 polymorphisms and lung cancer: A protocol for systematic review and meta-analysis.
Ma L; Jin G; Yang Y; Pang Y; Wang W; Zhang H; Liu J; Wu P; Wang Z; Wang K; Chang R; Li J; Zhu Z
Medicine (Baltimore); 2020 Dec; 99(50):e23289. PubMed ID: 33327254
[TBL] [Abstract][Full Text] [Related]
18. CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody.
Zhu LR; Thomas PE; Lu G; Reuhl KR; Yang GY; Wang LD; Wang SL; Yang CS; He XY; Hong JY
Drug Metab Dispos; 2006 Oct; 34(10):1672-6. PubMed ID: 16815959
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation--a mammalian cell-based mutagenesis approach.
Chiang HC; Wang CY; Lee HL; Tsou TC
Toxicol Appl Pharmacol; 2011 Jun; 253(2):145-52. PubMed ID: 21473878
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 2A13 mediates the neoplastic transformation of human bronchial epithelial cells at a low concentration of aflatoxin B1.
Zhang Z; Lu H; Huan F; Meghan C; Yang X; Wang Y; Wang X; Wang X; Wang SL
Int J Cancer; 2014 Apr; 134(7):1539-48. PubMed ID: 24114584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
